Indian Journal of Critical Care Medicine

Register      Login

SEARCH WITHIN CONTENT

FIND ARTICLE

Volume / Issue

Online First

Archive
Volume  28 (2024)
Volume  27 (2023)
Volume  26 (2022)
Volume  25 (2021)
Volume  24 (2020)
Volume  23 (2019)
Volume  22 (2018)
Volume  21 (2017)
Volume  20 (2016)
Volume  19 (2015)
Volume  18 (2014)
Volume  17 (2013)
Volume  16 (2012)
Volume  15 (2011)
Volume  14 (2010)
Volume  13 (2009)
Volume  12 (2008)
Volume  11 (2007)
Volume  10 (2006)
Volume  9 (2005)
Volume  8 (2004)
Related articles

VOLUME 28 , ISSUE 5 ( May, 2024 ) > List of Articles

PEDIATRIC CRITICAL CARE MEDICINE

Survey of Pediatric Status Epilepticus Treatment Practices and Adherence to Management Guidelines (Pedi-SPECTRUM e-Survey)

Renu Suthar, Suresh Kumar Angurana, Karthi Nallasamy, Arun Bansal, Jayashree Muralidharan

Keywords : Antiseizure medications, Midazolam, Nonconvulsive status epilepticus, Status epilepticus, Thiopentone

Citation Information : Suthar R, Angurana SK, Nallasamy K, Bansal A, Muralidharan J. Survey of Pediatric Status Epilepticus Treatment Practices and Adherence to Management Guidelines (Pedi-SPECTRUM e-Survey). Indian J Crit Care Med 2024; 28 (5):504-510.

DOI: 10.5005/jp-journals-10071-24707

License: CC BY-NC 4.0

Published Online: 30-04-2024

Copyright Statement:  Copyright © 2024; The Author(s).


Abstract

Aim: Survey of treatment practices and adherence to pediatric status epilepticus (PSE) management guidelines in India. Methods: This eSurvey was conducted over 35 days (15th October to 20th November 2023) and included questions related to hospital setting; antiseizure medications (ASMs); ancillary treatment; facilities available; etiology; and adherence to PSE management guidelines. Results: A total of 170 respondents participated, majority of them were working in tertiary level hospitals (94.1%) as pediatric intensivists (56.5%) and pediatricians (19.4%), and were in clinical practice for 2–10 years (46.5%). Majority use intravenous (IV) midazolam and levetiracetam as first- and second-line ASMs (67.1 and 51.2%, respectively). In cases with refractory status epilepticus (RSE), the most commonly used ASM is midazolam infusion (92.4%). For super-refractory status epilepticus (SRSE), the commonly used third-line ASMs include midazolam infusion (34.1%), thiopentone infusion (26.5%), high dose phenobarbitone (18.2%), and ketamine infusion (15.3%). Overall, in cases with SRSE, 44.7% respondents use ketamine infusion, 42.5% use add-on oral topiramate, and 34.7% use high-dose phenobarbitone (1–3 mg/kg/hour) infusion. Most respondents targeted both clinical and EEG seizure control (48.8%). Ancillary treatment used for SRSE included IV pyridoxine (57.1%), methylprednisolone (45.3%), IVIG (42.4%), ketogenic diet (40.6%), and second-line immunomodulation (33.5%). Most common causes were febrile SE, viral encephalitis, and febrile illness-related epilepsy syndrome (60.6%, 52.4%, and 37.1%, respectively). Facilities available included pediatric intensive care units (PICU) (97.1%), mechanical ventilation (98.2%), pediatric neurologist (68.8%), MRI brain (86.5%), EEG (69.4%), and viral PCR (58.2%). The compliance with guidelines for timing of initiation of ASM ranged from 63.5 to 88.8%. Conclusion: Intravenous midazolam bolus/es, levetiracetam, and midazolam infusion are commonly used first-, second-, and third-line ASMs, respectively. There were wide variations in use of ASMs for RSE and SRSE, ancillary treatment, and compliance to PSE management guidelines.

PDF Share
  1. Chin RFM. The outcomes of childhood convulsive status epilepticus. Epilepsy Behav 2019;101(Pt B):106286. DOI: 10.1016/j.yebeh.2019.04.039.
  2. Kling R, Ritvanen J, Mustonen H, Kämppi L. Long-term outcome of convulsive status epilepticus: A 10-year follow-up. Epileptic Disord 2022;24(6):1046–1059. English. DOI: 10.1684/epd.2022.1482.
  3. Glauser T, Shinnar S, Gloss D, Alldredge B, Arya R, Bainbridge J, et al. Evidence-based guideline: Treatment of convulsive status epilepticus in children and adults: Report of the Guideline Committee of the American Epilepsy Society. Epilepsy Curr 2016;16(1):48–61. DOI: 10.5698/1535-7597-16.1.48.
  4. Van de Voorde P, Turner NM, Djakow J, de Lucas N, Martinez-Mejias A, Biarent D, et al. European Resuscitation Council Guidelines 2021: Paediatric life support. Resuscitation 2021;161:327–387. DOI: 10.1016/j.resuscitation.2021.02.015.
  5. Mishra D, Sharma S, Sankhyan N, Konanki R, Kamate M, Kanhere S, et al. Multi-disciplinary group on management of status epilepticus in children in India. Consensus guidelines on management of childhood convulsive status epilepticus. Indian Pediatr 2014;51(12):975–990. DOI: 10.1007/s13312-014-0543-4.
  6. Singhi S, Angurana SK. Principles of management of central nervous system infections. Indian J Pediatr 2019;86(1):52–59. DOI: 10.1007/s12098-017-2583-y.
  7. Lyttle MD, Rainford NEA, Gamble C, Messahel S, Humphreys A, Hickey H, et al. Paediatric emergency research in the United Kingdom & Ireland (PERUKI) collaborative. Levetiracetam versus phenytoin for second-line treatment of paediatric convulsive status epilepticus (EcLiPSE): A multicentre, open-label, randomised trial. Lancet 2019;393(10186):2125–2134. DOI: 10.1016/S0140-6736(19) 30724-X.
  8. Dalziel SR, Borland ML, Furyk J, Bonisch M, Neutze J, Donath S, et al. Levetiracetam versus phenytoin for second-line treatment of convulsive status epilepticus in children (ConSEPT): An open-label, multicentre, randomised controlled trial. Lancet 2019;393(10186):2135–2145. DOI: 10.1016/S0140-6736(19)30722-6.
  9. Angurana SK, Suthar R. Efficacy and safety of levetiracetam vs. phenytoin as second line antiseizure medication for pediatric convulsive status epilepticus: A systematic review and meta-analysis of randomized controlled trials. J Trop Pediatr 2021;67(2):fmab014. DOI: 10.1093/tropej/fmab014.
  10. McTague A, Martland T, Appleton R. Drug management for acute tonic-clonic convulsions including convulsive status epilepticus in children. Cochrane Database Syst Rev 2018;1(1):CD001905. DOI: 10.1002/14651858.CD001905.pub3.
  11. Patten W, Naqvi SZ, Raszynski A, Totapally BR. Complications during the management of pediatric refractory status epilepticus with benzodiazepine and pentobarbital infusions. Indian J Crit Care Med 2015;19(5):275–277. DOI: 10.4103/0972-5229.156476.
  12. Masapu D, Gopala Krishna KN, Sanjib S, Chakrabarti D, Mundlamuri RC, Manohar N, et al. A comparative study of midazolam and target-controlled propofol infusion in the treatment of refractory status epilepticus. Indian J Crit Care Med 2018;22(6):441–448. DOI: 10.4103/ijccm.IJCCM_327_17.
  13. Nuñez P, Hansen J, Aprea V, Álvarez Ricciardi MB, Oviedo S, Fustiñana A, et al. Management of status epilepticus in childhood: A survey conducted at pediatric hospitals in the City of Buenos Aires. Arch Argent Pediatr 2023;121(2):e202202696. DOI: 10.5546/aap.2022-02696.eng.
  14. Dedeoglu Ö, Akça H, Emeksiz S, Kartal A, Kurt NÇ. Management of status epilepticus by different pediatric Departments: Neurology, intensive care, and emergency medicine. Eur Neurol 2023;86(5): 315–324. DOI: 10.1159/000533191.
  15. Kowoll CM, Klein M, Salih F, Fink GR, Stetefeld HR, Onur OA, et al. IGNITE status epilepticus survey: A nationwide interrogation about the current management of status epilepticus in Germany. J Clin Med 2022;11(5):1171. DOI: 10.3390/jcm11051171.
  16. Philpott NG, Dante SA, Philpott D, Perin J, Bhatia P, Henderson E, et al. Treatment guideline nonadherence pretransport associated with need for higher level of care in children transferred to a pediatric tertiary care center for status epilepticus. Pediatr Emerg Care 2023;39(10):780–785. DOI: 10.1097/PEC.0000000000002952.
  17. Tyson M, Trenear R, Skellett S, Maconochie I, Mullen N. Survey about second-line agents for pediatric convulsive status epilepticus. Pediatr Emerg Care 2023;39(4):247–252. DOI: 10.1097/PEC.0000000000002745.
  18. Trinka E, Cock H, Hesdorffer D, Rossetti AO, Scheffer IE, Shinnar S, et al. A definition and classification of status epilepticus – Report of the ILAE Task Force on Classification of Status Epilepticus. Epilepsia 2015;56(10):1515–1523. DOI: 10.1111/epi.13121.
  19. Pujar SS, Martinos MM, Cortina-Borja M, Chong WKK, De Haan M, Gillberg C, et al. Long-term prognosis after childhood convulsive status epilepticus: A prospective cohort study. Lancet Child Adolesc Health 2018;2(2):103–111. DOI: 10.1016/S2352-4642(17)30174-8.
  20. Vasquez A, Farias-Moeller R, Tatum W. Pediatric refractory and super-refractory status epilepticus. Seizure 2019;68:62–71. DOI: 10.1016/j.seizure.2018.05.012.
  21. Crawshaw AA, Cock HR. Medical management of status epilepticus: Emergency room to intensive care unit. Seizure 2020;75:145–152. DOI: 10.1016/j.seizure.2019.10.006.
  22. Payne ET, Zhao XY, Frndova H, McBain K, Sharma R, Hutchison JS, et al. Seizure burden is independently associated with short term outcome in critically ill children. Brain 2014;137(Pt 5):1429–1438. DOI: 10.1093/brain/awu042.
  23. Fung FW, Carpenter JL, Chapman KE, Gallentine W, Giza CC, Goldstein JL, et al. Survey of pediatric ICU EEG monitoring-reassessment after a decade. J Clin Neurophysiol 2023;10:1097/WNP.0000000000001006. DOI: 10.1097/WNP.0000000000001006.
  24. van Baalen A. Febrile infection-related epilepsy syndrome in childhood: A clinical review and practical approach. Seizure 2023;111:215–222. DOI: 10.1016/j.seizure.2023.09.008.
  25. Barcia Aguilar C, Sánchez Fernández I, Loddenkemper T. Status epilepticus-work-up and management in children. Semin Neurol 2020;40(6):661–674. DOI: 10.1055/s-0040-1719076.
  26. Ferlisi M, Shorvon S. The outcome of therapies in refractory and super-refractory convulsive status epilepticus and recommendations for therapy. Brain 2012;135(Pt 8):2314–2328. DOI: 10.1093/brain/aws091.
  27. AlMohaimeed BA, Hundallah KJ, Bashiri FA, AlMohaimeed SA, Tabarki BM. Evaluation of adherence to pediatric status epilepticus management guidelines in Saudi Arabia. Neurosciences (Riyadh) 2020;25(3):182–187. DOI: 10.17712/nsj.2020.3.20190106.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.